TPO concentrations and response to romiplostim

Authors


  • Conflict of interest: D.K. has consulted for and received research funding from Amgen, GlaxoSmithKline, Pfizer, Shionogi, ONO, 3SBios, Eisai. A.M. is a consultant for Amgen. A.L. was an employee of and is a stockholder for Amgen. Medical writing assistance provided by Susanna Mac of Amgen.

No abstract is available for this article.

Ancillary